huTIGIT-CHO-K is a recombinant monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically engineered for research and therapeutic development targeting the TIGIT (T-cell immunoreceptor with Ig and ITIM domains) pathway. This molecule is primarily used in immuno-oncology studies to modulate immune responses by blocking the interaction between TIGIT and its ligands, such as CD155 and CD112, which are often overexpressed on tumor cells. By inhibiting this pathway, huTIGIT-CHO-K helps restore T-cell and NK-cell activation, enhancing anti-tumor immunity. It serves as a critical tool in preclinical development for cancer immunotherapies, particularly in evaluating combination treatments with other immune checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 antibodies. Its high specificity and human origin make it suitable for assessing pharmacokinetics, biodistribution, and efficacy in humanized mouse models. Additionally, huTIGIT-CHO-K supports the development of biologics manufacturing processes, including purification, quality control, and stability testing, due to its consistent production in CHO systems.